Business Wire

TX-SONAR

1.5.2024 15:01:34 CEST | Business Wire | Press release

Share
Lynne Doherty Joins Sonar as President of Field Operations

Sonar announced today that Lynne Doherty will join the organization as President of Field Operations. In her new role, Lynne will be responsible for driving revenue, and ensuring that Sonar's customers are successful in their pursuit of Clean Code. The leading provider of Clean Code solutions, Sonar accelerates mission-critical software development, reduces technical debt, and improves code quality and code security. Lynne will lead the company’s demand generation, global sales, solutions engineering, customer success, and customer support teams globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501287633/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Lynne Doherty joins Sonar as President of Field Operations to accelerate revenue growth and global expansion. (Photo: Business Wire)

“Lynne has an outstanding track record of leading high-performing go-to-market organizations and driving positive business outcomes. We are excited that she is joining Sonar and believe she’s the ideal leader to help us in our next phase of growth,” said Tariq Shaukat, co-CEO of Sonar. “Having started her career as a Software Developer, she has a strong understanding of the value Sonar creates and a proven track record of working with customers to achieve that value.”

Lynne brings more than 20 years of sales leadership experience to Sonar, most recently as President, of Worldwide Field Operations at Sumo Logic, where she was focused on evolving the GTM organization for operational scale and speed. This included driving customer expansion and growing new logos, shifting the segmentation model, and starting a partner-first motion. Before that, she held various leadership roles at McAfee, where she drove over a billion dollars of revenue annually. In her time at McAfee, she led the team through several business evolutions, supported McAfee’s initial public offering, and multiple acquisitions.

“Sonar is a crucial tool for software developers and engineering teams that is especially necessary for AI-assisted code. With its Clean Code methodology, Sonar addresses a significant gap in the software development lifecycle, enhancing code quality and security hand-in-hand,” said Doherty. “Joining the Sonar team feels personal for me, in a sense, as I’m getting back to my roots as a developer, where I started my career. I’m thrilled to join the Sonar team and look forward to working alongside Tariq, Olivier, and the rest of the organization to deliver Clean Code.”

Before joining McAfee, Lynne held various sales and marketing leadership roles at Cisco, where she oversaw a team of more than 2,000 employees, and drove billions in revenue annually. While at Cisco, she also played a key role in the success of acquisitions of Duo Security, Umbrella, and Cloudlock. Lynne is an independent Director on the boards of CloudBees and the American Red Cross. She holds a B.S. in Mathematics and Computer Science from Temple University.

Over the last 15 years, Sonar has analyzed more than half-a-trillion lines of code across all industries and company sizes, resulting in a deep understanding of how code is written and managed. With that knowledge, Sonar has redefined what it means to write Clean Code in today’s software development life cycle, helping organizations accelerate mission-critical software development, manage proliferating risks, and build fast and reliable applications.

Sonar is currently hiring across a number of departments. You can learn more about joining the Sonar team here.

About Sonar

Sonar is a leading developer of open source solutions to help developers write Clean Code. Sonar’s solutions — SonarQube, SonarCloud, and SonarLint — support over 30 programming languages, frameworks, and infrastructure technologies. Trusted by more than 400,000 organizations globally to clean more than half a trillion lines of code, Sonar is integral to delivering higher quality, better-performing software.

To learn more about Sonar, please visit: https://www.sonarsource.com/products/all/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240501287633/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye